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Abstract
Human β-defensin 3 (hBD3) is a cationic host defence peptide and is part of the innate
immune response. HBD3 is present on a highly copy number variable block of six β-defen-
sin genes, and increased copy number is associated with the autoimmune disease psoria-
sis. It is not known how this increase influences disease development, but psoriasis is a T
cell-mediated disease and activation of the innate immune system is required for the initial
trigger that leads to the amplification stage. We investigated the effect of hBD3 on the
response of primary macrophages to various TLR agonists. HBD3 exacerbated the produc-
tion of type I Interferon-β in response to the viral ligand mimic polyinosinic:polycytidylic acid
(polyI:C) in both human and mouse primary cells, although production of the chemokine
CXCL10 was suppressed. Compared to polyI:C alone, mice injected with both hBD3 pep-
tide and polyI:C also showed an enhanced increase in Interferon-β. Mice expressing a
transgene encoding hBD3 had elevated basal levels of Interferon-β, and challenge with
polyI:C further increased this response. HBD3 peptide increased uptake of polyI:C by mac-
rophages, however the cellular response and localisation of polyI:C in cells treated contem-
poraneously with hBD3 or cationic liposome differed. Immunohistochemistry showed that
hBD3 and polyI:C do not co-localise, but in the presence of hBD3 less polyI:C localises to
the early endosome. Using bone marrow derived macrophages from knockout mice we
demonstrate that hBD3 suppresses the polyI:C-induced TLR3 response mediated by
TICAM1 (TRIF), while exacerbating the cytoplasmic response through MDA5 (IFIH1) and
MAVS (IPS1/CARDIF). Thus, hBD3, a highly copy number variable gene in human, influ-
ences cellular responses to the viral mimic polyI:C implying that copy number may have a
significant phenotypic effect on the response to viral infection and development of autoim-
munity in humans.
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Author Summary
Defensins are classically known as antimicrobial peptides due to their ability to rapidly kill
pathogens including bacteria, viruses and fungi. They are produced in the presence of
infectious agents at body surfaces exposed to the environment. Increasingly, their func-
tional repertoire is expanding, and they have been shown to modulate the immune system.
In humans, there is a block of six β-defensin genes that varies in copy number in the popu-
lation. Individuals with an increased number of β-defensin genes have an increased likeli-
hood of developing the skin autoimmune disease psoriasis. It is not known how this
increase in gene copy number influences development of the disease, and psoriasis is a
complex interplay of genomic and environmental factors that trigger disease progression
and include exposure to viruses. We examined whether a molecular pattern characteristic
of viruses produces an altered immune response in the presence of the defensin human β-
defensin 3 (hBD3). We find that hBD3 triggers a larger interferon defence response to this
viral mimic by increasing accessibility to a cellular receptor that recognises viral patterns.
Interferon is known to be important in autoimmunity and our work may explain why
individuals with increased β-defensin number are predisposed to develop psoriasis.
Introduction
HBD3 is a member of the β-defensin multigene family. The amphipathic, antiparallel β-sheet
structure, stabilised by disulfide bonds, via six canonical cysteines is conserved throughout evo-
lution [1] and between family members despite significant sequence diversity [2]. These power-
ful cationic antimicrobials directly kill fungi, bacteria and viruses, and recently it has become
clear that this gene family has roles in other processes including male fertility, immunomodula-
tion and inflammatory disease [3]. Defensins are primarily expressed from mucosal surfaces,
some exclusively in the reproductive tract and others in skin, intestine and gingival surfaces
[4–6]. Of β-defensin genes, hBD3 is probably the most versatile and studies both in vitro and in
vivo demonstrate its ability to chemoattractant immune cells [7]; encourage wound healing [8]
and modulate innate signalling [9–11]. HBD3 (gene name DEFB103) and its mouse orthologue
(Defb14) are promiscuous ligands with ability to bind the receptors CCR6, CCR2, CXCR4. In
addition, a dominant mutation in the DEFB103 gene in dogs and wolves causes an increase in
canine β-defensin 3 (CBD103) peptide level allowing off-target binding to melanocortin recep-
tor 1 (MC1R), which results in black coat colour [7, 12–15].
DEFB103 is present on hypervariable clusters of six β-defensin genes and alteration in copy
number may influence innate immune responses. Increased copy number of the cluster is asso-
ciated with psoriasis [16, 17]. Increased defensin peptide level has been reported in serum of
psoriasis patients, although the influence of defensins on the pathogenesis of the disease is not
understood. Psoriasis is a T cell-mediated disease predominantly orchestrated by Th-17 cells.
Amplification of the disease process is triggered by an initial phase modulated by an increase in
innate immune signalling through pattern recognition receptors (PRR) such as toll like recep-
tors (TLR) [18]. Psoriatic patients have an increase in dendritic cells and cationic antimicrobial
peptides in the skin [19]. It has been shown that self and viral nucleic acids trigger an increase
in the type I Interferon-α response of plasmacytoid dendritic cells (pDC) that are specialised
cells for Interferon-α production through TLR9[20]. Blocking production of Interferon-α by
these cells prevents T cell–dependent development of psoriasis in a xenograft model. The anti-
microbial peptide LL-37 has been identified as a molecule that encourages recognition of self
DNA and RNA through TLRs on pDC to induce release of Type I Interferon [21]. Recently
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antimicrobial peptides hBD2, hBD3 and lysozyme have also been shown to bind self-DNA and
activate pDC through TLR9 to release Interferon-α. The presence of these peptides in psoriatic
plaques suggests a concerted role for them in the pathogenesis of psoriasis [9, 19].
Here we determine the effect of hBD3 on the response of primary macrophages to known
pathogen-associated molecular patterns (PAMPs) to investigate the influence of hBD3 on sig-
nalling from innate immune receptors. We have previously shown that hBD3 suppresses the
TLR4-mediated response to bacterial lipopolysaccharide (LPS) which is mediated by both
MyD88(Myeloid Differentiation Primary Response 88) and TICAM1 (Toll-Like Receptor
Adaptor Molecule 1-also known as TRIF) [10]. We show that polyI:C in the presence of hBD3
has an exacerbated Interferon-β response and decreases CXCL10 production, in vitro and in
vivo in both mice and human primary cells. PolyI:C is a synthetic double stranded RNA
(dsRNA) and consequently a viral ligand mimic, which is recognised by endosomally located
TLR3 and also by cytoplasmic RIG-I-like receptors (RLRs) [22]. Recently high molecular
weight (HMW) or long poly:IC has been shown to preferentially access RLRs in conventional
dendritic cells [23]. The RLRs include RIG-I (also known as DDX58 (DEAD (Asp-Glu-Ala-
Asp) box polypeptide 58) and MDA5 (Melanoma Differentiation-Associated protein 5, also
known as IFIH1 -interferon induced with helicase C domain 1) [24]. HMW polyI:C is recog-
nised primarily by MDA5 (without the need for transfection) and secondarily (with transfec-
tion) by RIGI [23]. Activation of MDA5 and consequent interferon-β production has been
shown to be associated with autoimmune disorders [25–28]. Both TLR3 and RLR types of
receptor are MYD88 independent, with MDA5 and RIGI requiring the recruitment of the
adaptor protein MAVS (mitochondrial antiviral signalling protein -also known as VISA, IPS-1
and CARDIF). Signalling through the MAVS pathway in macrophages results in IRF3/7 driven
expression of type I Interferon and NF-κB induction of inflammatory cytokines and chemo-
kines [29, 30]. TLR3 specifically associates with the adaptor TICAM1 and mediates signal
transduction which activates IRF3 and NF-κB [30]. Our studies have been carried out using
HMW polyI:C throughout. We dissect the effect on the pathways responsible for the altered
response of macrophages to HMW polyI:C in the presence of hBD3 and reveal the mechanism
that enables increased Interferon-β and decreased CXCL10 production.
Results
HBD3 exacerbates polyI:C induced signalling in vitro and in vivo
We previously reported that hBD3 suppresses Toll Like Receptor 4 (TLR4)-induced signalling
in response to LPS both through MYD88 and TICAM1 pathways [10]. To investigate the effect
of hDB3 on other TLR pathways we exposed primary bone marrow derived macrophages from
mice (BMDM) to a variety of TLR ligands and found that the response to TLR 2, 2/6, 1/2, 7 or
9 ligands were not significantly altered in the presence of hBD3 (Fig 1A). In agreement with
our previous findings, hBD3 inhibited LPS-induced TNFα. In contrast, the response to HMW
polyI:C was significantly exacerbated in the presence of hBD3, increasing TNF-α; Interferon-β
and IL-6 production, however hBD3 significantly suppressed the CXCL10 (also known as
IP10) response to polyI:C (Fig 1B). The enhancing effect of hBD3 on polyI:C cytokine induc-
tion, was also seen in the human monocytic cell line THP1, where hBD3 significantly enhanced
polyI:C-induced TNFα, IL-6 and IL-8. However, in contrast to what we observe in mouse cells,
there was no significant effect of hBD3 on polyI:C-induced CXCL10 in human cells (Fig 1C).
In addition this enhancing effect was also seen on Interferon-β gene expression in primary
human peripheral blood monocyte derived macrophages (PBMDM), measured by qRT-PCR
(Fig 1D).
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The amount of hBD3 required to induce an enhanced Interferon-β response to polyI:C dif-
fered from that required to decreased CXCL10 response (Fig 2A). PolyI:C-induced CXCL10
was inhibited by 4μg/ml hBD3, but no longer inhibited at 2μg/ml hBD3, whereas concentra-
tions as low as 0.05 μg/ml hBD3 enhanced the Interferon-β response to polyI:C, although at
this concentration the effect is beginning to diminish. We tested the importance of the hBD3
cysteine-stabilised structure using hBD3 with the canonical defensin motif of six cysteines
(which form three intramolecular disulfide bonds) replaced with serines. This modified peptide
(hBD3 Cys:Ser) did not augment cytokine production in response to polyI:C, suggesting that
the enhancing effect of hBD3 on polyI:C signalling is dependent on the 3-dimensional struc-
ture of the hBD3 peptide (Fig 2B). This lack of effect was not due to the inability of the linear
peptide to rapidly enter the cell as TAMRA(tetramethylrhodamine azide)-labelled hBD3
Fig 1. hBD3 exacerbates stimulation by the viral mimic HMW polyI:C but does not increase stimulation by other TLR ligands (A) BMDM from
3 separate wildtype (wt) mice were incubated overnight with HKLM (Heat Killed Listeria monocytogenes) (TLR2 ligand), FSL-1 (synthetic lipoprotein
Pam2CGDPKHPKSF derived fromMycoplasma salivarium) (TLR2/6 ligand), LTA (Lipoteichoic acid from S. aureus (TLR2 ligand), Pam3CSK4 (synthetic
mimic of bacterial triacylated lipopeptide (TLR2/1 ligand), R848 (imidazoquinoline compound (TLR7 ligand), CpG (TLR9), TLR4 (LPS) or (B) HMW polyI:C
(pI:C) (TLR3/RLR agonist) (10μg/ml) with and without hBD3. (C) PMA-differentiated THP-1 cells were treated with HMW polyI:C (10μg/ml) with or without
5 mg/ml hBD3. TNF-α, IL-6, IL-8 and CXCL10 induction were measured by ELISA *p0.05, **p0.01 student t-test (D) Human primary PBMDMwere
exposed to polyI:C as indicated, Interferon-β (IFNβ) gene expression was measured by qRT-PCR. ***p<0.001, 2-way ANOVA.
doi:10.1371/journal.pgen.1005673.g001
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Cys:Ser peptide entered BMDM in 10 min (Fig 2B) similar to canonically folded hBD3, as
shown in our previous studies[10].
To test whether these in vitro effects were relevant in vivo, we injected wild type mice with
polyI:C in the presence of synthetic hBD3 peptide (Fig 3A). We found that TNF-α and
IL12p40 responses to polyI:C were significantly increased in the presence of synthetic hBD3.
Interestingly the cytokine CXCL10 was not decreased in the presence of hBD3 (Fig 3A)
although there was a trend for CXCL10 to be lower in the presence of hBD3- in keeping with
the significant reduction of this cytokine seen in the BMDM stimulated with polyI:C and
hBD3.
There is a concern that unless synthetic hBD3 is correctly oxidised and the correct disul-
phide bonding achieved, the properties of the peptide may be altered [7]. The importance of
structure is confirmed in our experiment with hBD3 Cys:Ser shown in Fig 2B. The oxidised
synthetic peptide we used here (obtained from Peptide Institute, Japan) gives details of prepa-
ration and oxidation [31] and implies correct cysteine bonding (C1-C5; C2-4 and C3-C6).
However, in order to investigate our effect with hBD3 oxidised in vivo, we expressed the gene
(DEFB103) that encodes hBD3, as a transgene in mice. Transgenic mice were made using the
pCAAG promoter (as described previously by Candille et al. [14]) by introducing a transgene
containing the genomic copy of DEFB103 into ES cells. The vector (shown in S1A Fig)
Fig 2. HBD3 effect on Interferon-β response to polyI:C is potent and is structure dependent. (A) BMDM from 3 separate mice were treated for 18hr with
pI:C (10μg/ml) in the presence and absence of reducing concentration of hBD3 or (B) modified hBD3-cys:ser as indicated and IFNβ, CXCL10 and TNFα
measured by ELISA. Image in B shows BMDM treated with 0.5μg/ml TAMRA-hBD3-cys:ser (10 min) observed by fluorescent microscopy. Scale bar 10μM.
doi:10.1371/journal.pgen.1005673.g002
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expresses hBD3 only after CRE recombinase-mediated deletion of the floxed DsRed, puromycin
STOP spacer. After deletion, hBD3 and EGFP are expressed as a polycistronic mRNA and
translated as independent proteins using an IRES site. We made several ES cell lines with the
DEFB103 expression construct and isolated a clone with strong expression by virtue of DsRed
expression and a single site of insertion of the transgene (located to the sub-telomeric region of
chromosome 12 by FISH and chromosome painting (S1B Fig). The control DsRed transgenic
mice were made with this ES clone. HBD3 transgenic mice were made from the same ES clone
after treatment with CRE recombinase. These cells had strong expression of EGFP and hBD3
and only the ES cells containing the CRE-excised vector showed expression of DEFB103
mRNA (S1C Fig). HBD3 mRNA expression was detected in all tissues tested from mice made
using the hBD3-Tg ES cells and hBD3 protein was detected in various tissues including
BMDM by immunohistochemistry (S1D Fig) using an hBD3 monoclonal antibody [32]. No
hBD3 was detected in DsRed-Tg control mice. The effect of polyI:C exposure in mice express-
ing physiologically secreted hBD3 was tested by exposing heterozygote hBD3-Tg and DsRed-
Tg mice to polyI:C (100μg, i.p.). The transgenic animals expressing hBD3 demonstrated an
increased level of both Interferon-β and TNF-α (Fig 3B). In addition, homozygous transgenic
hBD3 mice had a significantly raised basal level of Interferon-β compared to controls (Fig 3C).
A number of additional cytokines were investigated, including IL-6 and CXCL10. hBD3-Tg
Fig 3. HBD3 enhances the effects of polyI:C in vivo. (A) Wild type (wt) mice were injected intraperitoneally (i.p.) with polyI:C (pI:C) (100μg/mouse) in the
presence or absence of hBD3 (20μg/mouse) as indicated and cytokines measured by ELISA. (B) hBD3-Tg and DSRed-Tg control mice were injected i.p. with
pI:C (100μg/mouse), after 4hr serum cytokine levels were measured by ELISA. (C) Wt and hBD3-Tg mice were bled and serum IFN-βmeasured by
ELISA**p<0.01, *p<0.05 student t-test (n = 6 separate mice for each treatment group).
doi:10.1371/journal.pgen.1005673.g003
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mice treated with polyI:C showed a trend towards enhanced IL-6 induction and reduced
CXCL10 induction compared to controls, however these data did not reach significance
(see S2 Fig).
HBD3 and lipofectamine increase cellular uptake of polyI:C but induce
diverse inflammatory responses
HMW polyI:C enters macrophages without a transfection reagent, however complexing with
the cationic lipid, Lipofectamine 2000, enhances the amount of polyI:C entering cells by endo-
cytosis, allowing more ligand to be available to both endosomal and cytoplasmic receptors
[33]. We hypothesised that hBD3, being positively charged, may form complexes with polyI:C,
enhancing uptake in a similar way to lipofection. To investigate this, we compared cellular
uptake of FITC-labelled polyI:C in the presence of Lipofectamine 2000 and/or hBD3, by flow
cytometry. Compared to polyI:C alone, the addition of hBD3 significantly increased the
amount of labelled ligand per cell (Fig 4A). Lipofectamine alone also significantly augmented
the amount of polyI:C entering cells, with the amount of FITC-polyI:C uptake in the presence
Fig 4. hBD3 does not mimic the effects of lipofectamine. BMDM from 3 separate wildtype mice were treated with pI:C, or pI:C pre-complexed with
lipofectamine (at 1:100 dilution, 10μl/ml for 15min), in the presence or absence of hBD3. After 18hr cells were, (A) analysed by flow cytometry and culture
supernatants were analysed by ELISA to measure (B) CXCL10 and (C) IFNβ ***p<0.001, **p<0.01, *p<0.05. (D) BMDM, grown on glass slides, were
treated with 10mg/ml FITC-pI:C, without and with hBD3, without and with lipofectamine as labelled. Representative slides of each treatment visualised by
confocal microscopy, are shown.
doi:10.1371/journal.pgen.1005673.g004
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of Lipofectamine not differing significantly from the level of FITC-polyI:C in hBD3 treated
cells. Uptake in the presence of both lipofectamine and hBD3 was similar to either hBD3 or
lipofectamine alone, so no additive effect was apparent.
We further compared the effects of lipofectamine and hBD3 on the production of Inter-
feron-β and CXCL10 by polyI:C. Transfecting polyI:C with lipofectamine into wildtype
BMDM resulted in enhanced CXCL10 production (Fig 4B). In contrast hBD3 inhibited
CXCL10 induction by polyI:C. In the presence of a combination of lipofectamine and hBD3,
CXCL10 production was still inhibited compared to polyI:C and lipofectamine, but to a lesser
extent than hBD3 alone. In contrast, hBD3 and hBD3/lipofectamine significantly increased
Interferon-β production in response to polyI:C in BMDM (Fig 4C). Lipofectamine and polyI:C
did not demonstrate an enhanced Interferon-β response and lipofectamine decreased the
amount of Interferon-β produced in response to polyI:C.
To visualise the uptake of polyI:C by BMDM we used FITC-labelled polyI:C (green fluores-
cence). Stronger fluorescence, was observed in cells when either hBD3 or lipofectamine was
also present, supporting the flow cytometry data in Fig 4A showing both hBD3 and lipofecta-
mine increase the entry of polyI:C into the cells. HBD3 increased the intensity of cyloplasmic
polyI:C staining compared to either lipofectamine or polyI:C alone. In the presence of lipofec-
tamine, polyI:C had a more punctate pattern within the cell, consistent with endosomal loca-
tion. In the presence of hBD3, polyI:C appeared to have increased cytoplasmic distribution in
addition to foci of staining. These results show that lipofectamine and hBD3, both enhance the
amount of polyI:C that enters the cell but the different signalling responses triggered by each,
suggests that hBD3 is directing polyI:C towards cellular compartments, that are not those tar-
geted by the polyI:C-lipofectamine complexes.
HBD3 enters the cell more rapidly than polyI:C—hBD3 and polyI:C do
not co-localise
To further investigate the mechanism of the hBD3 effect on polyI:C we carried out fluorescence
co-localisation studies using TAMRA-labelled hBD3, FITC-labelled polyI:C and immunohis-
tochemistry for the early endosomal marker (EEA1). TAMRA-labelled hBD3 entered the cells
by 10mins (Fig 5Aii), whereas FITC-polyI:C was not visible in the cells until 30 minutes (Fig
5Biii). FITC-polyI:C added to the cells without hBD3 (Fig 5B and 5C), demonstrated FITC
fluorescence in punctate regions which stained to some extent with the early endosome marker
EEA1-1 antibody (Pearson coefficient, r = 0.615; Fig 5Civ). HBD3 alone (Fig 5A and 5D) also
localised to discrete regions however these did not co-localise with EEA1 staining (Pearson
coefficient, r = 0.205; Fig 5Div). Adding TAMRA-hBD3 and FITC-polyI:C together onto
BMDM, again showed more polyI:C entering the cell in the presence of hBD3 (Fig 5Biii, 5Cii
vs 5Eiii). However we could see no evidence for co-localisation of hBD3 and polyI:C (Pearson
coefficient, r = 0.073; Fig 5Evii). PolyI:C appeared more cytoplasmic in the presence of hBD3
than when it entered the cell alone and the co-localisation coefficient with EEA1-1 staining was
lower than in the absence of hBD3. (Pearson coefficient, r = 0.562 compared to r = 0.615 Fig
5Civ versus Fig 5Evi). In the presence of polyI:C, hBD3 remained localised in the discrete foci
similar to those seen with hBD3 treatment alone, and again hBD3 did not co-localise with
EEA1 (Pearson coefficient r = 0.05; Fig 5Eviii). This implies that hBD3, alters the localisation
of polyI:C allowing less polyI:C to access the early endosome. Although nucleic acids can
induce type I Interferon by activation of TLR signalling [34] in the endosome, Interferon-β and
IL-6 can also be produced by activation of cytoplasmic receptors.
hBD3 Exacerbates MDA5 but Suppresses TLR3 Signalling
PLOS Genetics | DOI:10.1371/journal.pgen.1005673 December 8, 2015 8 / 21
Fig 5. hBD3 enters cellsmore quickly than polyI:C and does not co-localise with polyI:C or endosomemarker EEA1.Wildtype BMDMwere treated with
(A)TAMRA-hBD3 or (B) FITC-polyI:C (pI:C) and imaged at 2 (i),10 (ii) and 30 (iii) minutes. BMDM treated for 30min with (C) FITC-pI:C (green) or (D) TAMRA-
hBD3 were stained with anti-EEA1 antibody. DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) staining shown in C(i) and D(i); FITC-pI:C (green) and
TAMRA-hBD3 (red) are shown in C(ii) and D(ii) respectively; EEA1 staining is shown in C(iii) and D(iii) (pseudocoloured red and green respectively); pI:C and
hBD3 colocalisation with EEA1 are demonstrated C(iv) in and D(iv) merged images respectively, with Pearson co-efficients of r = 0.615(C(iv)) and r = 0.205(D
hBD3 Exacerbates MDA5 but Suppresses TLR3 Signalling
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hBD3 exacerbates cytoplasmic MAVS-mediated signalling but
suppresses TICAM1-mediated signalling
To examine the consequences of the altered localisation of polyI:C by hBD3 and to determine
the signalling pathways responsible for production of Interferon-β and CXCL10, we used cells
from knockout mice specific for the two main pathways known to be involved. Firstly, we
determined the Interferon-β response of BMDM exposed to polyI:C in the absence of the TLR3
adaptor TICAM1 and found that this was reduced in Ticam1-/- cells compared to wild type
BMDM, indicating that the majority of the polyI:C effect on Interferon-β was not TICAM1
dependent. In the presence of hBD3, the polyI:C-induced Interferon-β response in Ticam1-/-
BMDM was still significantly enhanced compared to polyI:C alone (Fig 6A), which suggests
that hBD3 is not enhancing signalling through the TLR3/TICAM1 pathway. Conversely, in the
absence of MAVS, where Interferon production is only through TLR3/TICAM1 signalling, a
smaller amount of Interferon-β was induced by polyI:C. In the presence of hBD3 this Inter-
feron-β induction was significantly inhibited (Fig 6A), suggesting that hBD3 inhibits TLR3/
TICAM1 signalling. Treatment of BMDM from Ticam1(-/-)Mavs(-/-) double knockouts with
polyI:C did not induce Interferon-β indicating that all the Interferon-β response to polyI:C in
BMDM is dependent only on these two pathways (S4A Fig).
In contrast to Interferon-β, the induction of CXCL10 by polyI:C in wildtype BMDM was
significantly reduced in the presence of hBD3. In Ticam1(-/-) BMDM the response to polyI:C
was eliminated (Fig 6B) demonstrating that production of this cytokine is controlled primarily
by TLR3/TICAM1 activation. Supporting this finding, polyI:C-induced CXCL10 inMavs(-/-)
BMDM (a TLR3-TICAM1 dependent response) was not significantly different to wildtype cells
indicating that MAVS does not influence CXCL10 production and the production of CXCL10
in response to polyI:C inMavs(-/-) cells was still significantly inhibited by hBD3 (Fig 6B).
hBD3 exacerbates MDA5 receptor signalling in response to polyI:C
Both RIGI and MDA5 are upstream of MAVS, so to dissect the effects of hBD3 on MAVS sig-
nalling we used the specific RIGI ligand, 5’ triphosphate double stranded RNA (5’ppp) and
Mda5(-/-)mice [35]. Treatment of wildtype BMDM with 5’ppp resulted in a significant
increase in Interferon-β, TNFα and CXCL10, and as expected with this ligand, these responses
were dependent on the presence of MAVS (Fig 7A). The addition of hBD3 to the macrophages
shortly after transfection of 5’ppp, resulted in a significant decrease in cytokine and Interferon-
β production (Fig 7A), demonstrating that RIGI responses to 5’ppp are inhibited by the pres-
ence of hBD3. In contrast however, macrophages fromMda5(-/-) mice, revealed that Inter-
feron-β induced by polyI:C was reduced compared to wildtype cells, indicating that MDA5
signalling was responsible for the majority of the polyI:C induced Interferon-β production (Fig
7B). This residual response which is likely to be TLR3-TICAM1 signalling, was not amplified
in the presence of hBD3, indicating that MDA5 is required for the hBD3 enhancing effects on
polyI:C-induced Interferon-β.
(iv)). (E-i-viii) BMDMwere treated (30 min) with FITC-pI:C and TAMRA-hBD3 and immunostained with EEA1-1 antibody. One representative cell from each slide
is shown with filters allowing visualisation of single entities, E(i) DAPI staining for nucleus; E(ii) TAMRA-hBD3; E(iii) FITC-pI:C; E(iv) EEA1-1-Cy5 (blue), E(v)
merge of Eii,iii and iv. E(vi)-(viii) are merged images showing only two components to assess co-localisation, (vi) polyI:C (green), EEA1-1 (pseudocoloured red)
and hBD3 invisible; (vii) polyI:C (green) hBD3 (red) and EEA1-1 invisible; (viii) hBD3 (red) and EEA1-1(pseudocoloured green) and polyI:C invisible. Images are
representative of all cells treated, and visualised by confocal microscopy. Additional single colour images of EEA1 pseudocolouring to complement 5E are
shown in S3 Fig. Scale bars indicate 10microns.
doi:10.1371/journal.pgen.1005673.g005
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Discussion
We show here that hBD3 enhances the production of various cytokines in response to polyI:C
(TNF-α, IL6 in mouse cells and TNF-α, IL8 in human cells) and Interferon-β in both human
Fig 6. hBD3 inhibits TICAM1 signalling but enhancesMAVS-dependent signalling. BMDM fromwildtype,Mavs(-/-) or Ticam1(-/-) mice were treated with
10μg/ml pI:C in the presence or absence of hBD3. After 18hr cell culture supernatants were analysed by ELISA to measure (A) Interferon-β (IFNβ) and (B)
CXCL10 **p<0.01, *p<0.05 (In each group BMDMwere from 4 separate mice).
doi:10.1371/journal.pgen.1005673.g006
Fig 7. hBD3 inhibits RIGI signalling and enhancesMDA5 signalling. (A) BMDM from wildtype andMavs(-/-) mice were treated with 500ng/ml 5’ppp in the
presence and absence of 5μg/ml hBD3 (B) wildtype andMda5 (-/-) BMDMwere treated with pI:C in the presence and absence of hBD3. **p<0.01, *p<0.05,
Student t-test. (In each group BMDMwere from 4 separate mice).
doi:10.1371/journal.pgen.1005673.g007
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and mouse cells. We demonstrate that this effect is dependent on the correct, disulfide stabi-
lised structure of hBD3. Importantly, we show that this response is not specific to our synthetic
hBD3 peptide, as transgenic animals expressing hBD3 from a genomic transgene, also demon-
strate an increased type I Interferon response when injected with polyI:C. It was important to
reproduce the results shown with our synthetic hBD3 peptide in this transgenic system to vali-
date the augmenting effects of hBD3 as it has been demonstrated that synthetic peptides may
be incorrectly folded giving misleading results [7]. The synthetic hBD3 peptide we use here,
gives equivalent functional results to hBD3 produced in vivo.
When we dissect the pathways known to be activated by polyI:C, it is evident that although
signalling through the RLR co-adaptor MAVS mediated pathway is up-regulated in the pres-
ence of hBD3, signalling through the endosomally located TLR3/TICAM1 pathway is sup-
pressed. The inhibition of the TICAM1-mediated signalling pathway supports our findings
with LPS, where we previously reported that hBD3-mediated inhibition of LPS signalling
through TLR3/TICAM1 was lost in Ticam1 KOmice and could be inhibited by hBD3 cDNA
in HEK293 cells [10].
In our experiments here, we use HMW (long) polyI:C which activates MDA5 with or with-
out transfection and show that in BMDM, MDA5 is predominantly responsible for the Inter-
feron-β response. Interestingly, it has been demonstrated previously that LMW and HMW
polyI:C are recognised by different receptors with HMW polyI:C being recognised by MDA5
and LMW polyI:C by RIGI [24]. In addition large RNA structures generated by viral replica-
tion are believed to be important in effectively triggering MDA5 [36]. Recently Zou et al
reported that forced delivery of HMW polyI:C to the cytoplasm with transfection was not nec-
essary for RLR stimulation in GM-DCs and CD11bhiCD24lo DCs, although LMW polyI:C
required transfection to interact with MDA5 [23]. We show here that similarly to the DCs,
BMDM also take up HMW polyI:C effectively without transfection and activate MDA5. HBD3
exacerbates the signalling through MDA5. These researchers also report release of endosomal
Cathepsin D and induction of necrosis by the activation of MDA5. We see no evidence of cell
death (using an LDH assay, see S5 Fig) using polyI:C at 10μg/ml, but this is 5-fold less than
that used by Zou et al [23].
Cationic lipids such as Lipofectamine are known to cause endosomal localisation [33].
Although hBD3 is a cationic peptide we do not observe similar outcomes when we compare
the effects of hBD3 with the actions of lipofectamine on polyI:C stimulation of macrophages.
In wild type cells stimulated with polyI:C, hBD3 increased Interferon-β and decreased CXCL10
production. In contrast, polyI:C and lipofectamine increased CXCL10 production and
decreased Interferon-β. This effect is likely to be due to the change in localisation of polyI:C as
a result of being in the presence of lipofectamine or hBD3 (see Fig 8). Our immunostaining
demonstrates that hBD3 encouraged polyI:C to be more cytoplasmic compared to lipofecta-
mine which causes increased endosomal localisation. Despite the likely electrostatic interaction
of polyI:C and the highly charged hBD3 (+11) in the cell, our cellular uptake experiments
using fluorescently labelled derivatives revealed that at 30min after addition to the cells hBD3
and polyI:C do not co-localise appreciably. It is possible that initially they may have interacted,
allowing polyI:C to access the cell as hBD3 has been described as having cell penetrating prop-
erties [37]. In the presence of hBD3, polyI:C does not localise to the early endosome so presum-
ably the cytoplasmic location of the ligand allows an increase in interaction with MDA5. It is
possible that cationic hBD3 complexed with polyI:C, enables the ligand to rapidly escape the
acidic endolysosome, perhaps in a similar way to pH-dependent fusogenic peptides that assist
macromolecules to access the cytoplasm [33]. However we see polyI:C localised to the early
endosome (by EEA1 positive immunostaining) in the presence of hBD3 implying that the
structure of the early endosome is not disrupted by the presence of hBD3.
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The main consequence of increased MDA5 signalling in response to polyI:C is increased
IFN-β. This increase is additive when lipofectamine is also present (S4B Fig). However no
increase is observed in the absence of MAVS which implies that the exacerbated response
requires the RLR. It may be that lipofectamine complexes the polyI:C to create higher order
structures that activate MDA5 more optimally when [36] hBD3 increases its cytoplasmic
localisation.
MDA5 is important in relation to autoimmunity and mutations that inactivate or reduce
expression of MDA5 have been shown to protect individuals from type I diabetes mellitus risk
[38, 39]. In addition, a mutant form of MDA5 in mice that is active without viral infection
induces a type I Interferon-dependent autoimmunity with similarities to lupus [25]. However
Interferon-β has also been described as a protector against some types of inflammation such
as dextran sodium sulphate induced colitis [40–42] and this protection can be observed in
mice that express increased Interferon-β in response to dsRNA-producing intestinal bacteria
[40–42].
Increased copy number of the cluster of β-defensins on human chromosome 8 is linked to
increased incidence of the autoimmune disease psoriasis and effective treatment of psoriasis
with UV irradiation is linked to suppression of type I Interferon and Th17 cells [43]. In
Fig 8. Schematic of hBD3 and Lipofectamine 2000 interaction with HMW polyI:C. Pale arrows indicate relative amounts of HMW polyI:C accessing
different areas of the cell under our three different treatment conditions. The cell membrane is indicated by a double line, MAVS is located adjacent to the
mitochondria. MDA5 is free in cytoplasm but goes to MAVS adaptor to generate the signalling cascade that results in IRF activation and production of
Interferon-β (IFNβ). The black arrows indicate the strength of signalling that results in IFNβ or CXCL10 production with the dotted line indicating least
signalling and the widest line indicating most signalling. Compared to polyI:C alone, hBD3 increases IFNβ production fromMDA5 signalling and despite
reducing the amount from TLR3, overall IFNβ levels rise. CXCL10 production from TLR3 is reduced by polyI:C in the presence of hBD3 because less is
located at the endosome available for TLR3 signalling. In the presence of Lipofectamine, polyI:C production by TLR3/TICAM1 of CXCL10 increases due to
increased endosomal signalling.
doi:10.1371/journal.pgen.1005673.g008
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addition the most effective treatments currently for psoriasis are monoclonal antibodies
directed against IL-17 cytokine production or IL-12p40 (the cytokine subunit common to both
IL-12 and IL-23) [18, 44]. It is thus potentially highly significant that we see strong elevation of
IL12-p40 subunit in mice injected with both hBD3 and polyI:C. It is also possible that the other
defensins on the CNV cluster may also demonstrate this effect and we have shown that hBD2
also heightens the response of mouse BMDM to polyI:C (S6 Fig).
It has recently been shown that human pDC produce Interferon-α in response to self or
other DNA through TLR9 [9, 19]. We show here that macrophages increase the Interferon-β
response to polyI:C in the presence of hBD3 through MDA5. Production of type I Interferons
is normally the consequence of pattern recognition receptors binding virally produced nucleic
acid pathogen associated molecular patterns (PAMP), such as double stranded RNA (dsRNA)
produced during viral replication. Psoriasis has been reported to be exacerbated by the use of
Interferon-α as therapy for Hepatitis C [45] and by Interferon-β therapy for multiple sclerosis
[46]. Investigation of the psoriasis transcriptome has identified an increase in RIG-I like recep-
tors (RLR), which also recognise viral PAMP leading to type 1 Interferon production [47]. Dur-
ing a pathogen infection, hBD3 expression increases [32, 48], and hBD3 has been shown to
demonstrate potent anti-viral action in vitro [49]. Expression in pDC, monocytes and epithelial
cells of the non-copy number variable defensin hBD1 has been shown to increase in response
to virus exposure, while expression of the murine orthologue of DEFB103 (Defb14) increases in
response to polyI:C [50, 51]. MDA5 is specialised for protecting mice against infection with
various RNA viruses including picornaviruses (including Theiler’s and Mengo viruses and
Encephalomyocarditis virus (EMCV)) as well as paramyxovirus and Norovirus [52, 53].
MDA5 knockout mice are highly susceptible to EMCV [35, 54]. During infection, rapid killing,
detection and innate response are essential; therefore in this regard, high hBD3 copy number
and potentiation of PRR may be beneficial. However an undesirable effect of increased copy
number of the defensin cluster (and concomitant increase in expression of defensin peptides)
may be over stimulation of PRRs leading to exuberant production of type I interferons. This
double edged sword may provide protection against pathogens in the short term, but in the
longer term contribute to the development of psoriasis in individuals with an increased copy
number of the β-defensin cluster.
Materials and Methods
Animal and human ethical statements
Animal studies were covered by Project License (PPL 60/4475), granted by the UK Home
Office under the Animal Scientific Procedures Act 1986, and locally approved by the University
of Edinburgh Ethical Review Committee. Human venous blood was collected with written
patient consent from healthy volunteers according to Lothian Research Ethics Committee
approvals ]08/S1103/38.
Reagents
Ultra pure Lipopolysaccharide (LPS) from E. coli 0111:B4, Lipoteichoic acid (LTA), Pam3CSK4,
FSL-1, HKLM, polyI:C (HMW), FlTC-labelled polyI:C (HMW), R848, CpG and 5’ triphos-
phate double stranded RNA (5’ ppp-dsRNA) were purchased from InvivoGen (San Diego,
USA), M-CSF, ELISA DuoSets and IFNβ antibodies were obtained from R&D Systems,
(Abington, UK). Fluorescently labelled secondary antibodies were purchased from Jackson
ImmunoResearch Laboratories (PA, USA). hBD3 (GIINTLQKYYCRVRGGRCAVLSCLPKEE
QIGKCSTRGRKCCRRKK) was from Peptides International, and cys-ser hBD3 and cys-ser-
TAMRA hBD3 were from Almac (Almac Group Ltd, Craigavon, UK).
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TAMRA-hBD3 synthesis, purification, and folding
The peptide was produced on a CEM Liberty1 microwave peptide synthesizer using standard
Fmoc (fluorenylmethyloxcarbonyl chloride) chemistry. Amino acids were purchased from
AAPPTec and were assembled on H-Rink amide ChemMatrix resin. Fmoc protecting groups
were removed using 20% piperidine and 0.1 M hydroxybenzotriazole (HOBt) in dimethylfor-
mamide (DMF). Amino acids were coupled using 5 molar equivalents of diisopropylcarbodii-
mide (DIC) and 10 molar equivalents of HOBt in DMF. The N-terminal labelling of peptides
with fluorescent dye was performed on resin-bound peptide using 4 equivalents of 5-(and-6)-
carboxytetramethylrhodamine, succinimidyl ester (5(6)-TAMRA SE purchased from Biotium)
and 6 equivalents of diisopropylethylamine (DIEA) in DMF, incubating for 2 hours. The
peptide resin was then rinsed with DMF to remove excess fluorescent dye, washed with
dichloromethane (DCM), and dried. Cleavage of the peptide from resin was performed in a tri-
fluoroacetic acid (TFA)/ triisopropylsilane (TIS)/ 1, 2-ethanedithiol (EDT)/ phenol (90:4:4:2)
mixture for 90 min. The resin was filtered and the filtrate was added to 90 mL of cold dry
diethyl ether. The precipitate was collected by centrifugation and the diethyl ether was dis-
carded. The peptide was purified on a C18 reverse phase HPLC column and the correct molec-
ular weight was confirmed by ESI-MS. Oxidative folding was achieved in folding buffer (0.5–
1.0 M guanidine hydrochloride (GuHCl), 0.1 M Tris, 1 mM glutathione (GSH), 0.1 mM oxi-
dized glutathione (GSSG), pH 8.5) at a peptide concentration of 0.1 mg/mL and stirred for 48
hours. Folding was monitored by reverse phase HPLC, which revealed one major species that
was used in subsequent experiments. Folding procedures were developed to give the correct
HBD3 structure, as verified previously by nuclear magnetic resonance structure determination
(Nix et al., 2013). The folded products were purified on a C18 reverse phase HPLC column and
identified as fully oxidized peptides by ESI-MS. Quantitative concentrations were determined
with amino acid analysis at the molecular structure facility at UC Davis.
Mouse strains
TheMavs−/− (Cardif, Ips-1, or Visa) mutant line was generated by the Tschopp group in Lau-
sanne. It is homozygous-viable null mutant in the C57B6J background. Ticam1 (Trif) -/- mice
and MDA5-/- mice were used with the generous permission of Professor Shizuo Akira (Osaka
University, Japan)[35, 55]. hBD3-Tg and DsRed-Tg were constructed by electroporation of
ScaI linearised parental vector, which has a 1.5 Kb genomic fragment of the entire hBD3 gene
DEFB103 including exons 1 and 2 and the intervening intron cloned into pTLC plasmid (a
kind gift from Josh Brinkman, Danish Stem Cell Centre, DanStem, University of Copenhagen)
using DEFB103 primers with 5' NheI and PacI sites for cloning, into ES cells. Cells that strongly
expressed DsRed were selected by FACS and used to make DsRed-Tg mice. Transient cre treat-
ment of these cells produced DsRed negative cells due to lox -mediated excision of the DsRed
gene and allowed expression of hBD3 and EGFP (see S1 Fig). The ES cells were made into mac-
rophages using the method of (Yeung et al 2015) which were strong expressors of EGFP.
Clones before and after CRE treatment were injected into blastocysts at the University of Edin-
burgh MRC Evans Building, Transgenic Unit.
Cell-lines and primary cell preparation
THP-1 cells were grown in RPMI with 10% fetal bovine serum (FBS) and differentiated into
macrophages by the addition of 150nM PMA, 2 days before treatment. Mouse primary macro-
phages (BMDM) were generated from femur bone marrow grown for 8 days in DMEM with
10% fetal bovine serum and 20ng/ml M-CSF. Cells, seeded at 2 x 105 into 48 well plates, were
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grown without M-CSF for 24 hours prior to treatment. Replicate experiments were done with
separate primary cell preparations from at least 3 mice for each experiment.
Mouse BMDM treatment and ELISA
Mouse BMDM, seeded at 2 x 105 cells into 48 well plates were treated in serum free media with
TLR or RIGI agonists at the concentrations indicated in the figures, in the presence or absence
of hBD3 (5μg/ml). After an 18 hour incubation at 37°C, 5% CO2, TNF-α, IL-6, CXCL10 and
Interferon-β were measured using mouse DuoSet ELISA (R&D Systems). Statistical signifi-
cance was determined by an unpaired t-test using GraphPad software, with values expressed as
mean +/- SEM and p< 0.05 considered significant.
Human PBMDM isolation, treatment and quantitative PCR
Human venous blood was collected from healthy volunteers according to Lothian Research
Ethics Committee approval, using sodium citrate anticoagulant (Phoenix Pharma, Gloucester,
UK), and cells were separated by Dextran sedimentation, followed by discontinuous, isotonic
Percoll gradient centrifugation as previously described [56]. PBMC were incubated at 4×106/
mL in IMDM (PAA Laboratories, Somerset, UK) at 37°C, 5% CO2, for 1 h. Non-adherent cells
were removed and adherent monocytes cultured for 6 days in IMDMwith 10% autologous
serum to generate monocyte-derived Mφ. PolyI:C was applied in concentrations indicated and
cells harvested at 18 hours. RNA was isolated and human Interferon-β gene expression was
measured using the Applied Biosystems Taqman Gene Expression Assay following the manu-
facturer’s instructions.
Immunostaining
Cytospins of mouse BMDM were fixed in 4% PFA, washed, then blocked for 2 hours at room
temperature (RT) in 10% donkey serum (Sigma, Poole, UK) in PBST (0.1% Tween in PBS).
Slides were then incubated overnight at 4°C with hBD3 antibody (1:200) (DSHB, Iowa Univer-
sity, USA). After washing, slides were incubated with TxRd labelled anti-mouse antibody
(1:400) for 2 hours at RT, further washed then mounted with Vectashield containing 1μg/ml
DAPI. hBD3 immunostaining was visualised using a Zeiss Axioplan 2 microscope (Carl Zeiss
UK Ltd., Welwyn Garden City, UK) equipped with Ludl filter wheel (Ludl Electronic Products
Ltd, Hawthorne, NY, USA) and Chroma 83000 triple bandpass filter set (Chroma Technology
Corp, Rockingham, VT, USA). In-house scripts written for IPLab (Scanalytics Corp, Fairfax
VA, USA) were employed for image capture and image processing.
Cellular localisation and confocal microscopy
BMDM (2 x 104 cells/well) were cultured overnight on 8 well glass chamber slides (Nunc Inc,
IL, USA) in DMEM with 10% FCS. Cells were treated with FITC-polyI:C (2.5μg/ml) in Opti-
mem media (Life Technologies) with or without lipofectamine 2000 (Invitrogen, at 1:100 dilu-
tion, 10μl/ml) in the presence or absence of hBD3 or TAMRA-labelled HBD3 (0.5μg/ml). After
2, 10, 15 or 30 mins cells were washed in PBS and fixed in 4% PFA. For early endosome stain-
ing, cells were blocked with 10% donkey serum and incubated with anti-EEA11 antibody
(Abcam, UK) for 1 hr at RT, then 30 min with donkey anti-rabbit Cy5. Cells were imaged
using a 40x 1.3NA oil immersion objective on a Nikon A1R confocal microscope using Nikon
Nis-Elements AR software for image acquisition (Nikon Instruments Europe, Netherlands).
Image analysis was carried out in ImageJ (http://imagej.nih.gov/ij/). Pearsons coefficients were
calculated using the JaCoP ImageJ plugin [57].
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PolyI:C delivery in vivo
Male C57 Black/6 mice (6–8 weeks old) and hBD3 transgenic male mice (8 weeks) were
injected intraperinoneally (i.p.) with polyI:C (100μg/mouse) in 200μl of physiological saline.
Half of the C57 Black/6 mice also received an i.p injection of synthetic hBD3 (20μg/mouse).
After 4 hr, mice were killed by cervical dislocation, exsanguinated and serum levels of TNFα
and Interferon-βmeasured by ELISA.
Analysis of polyI:C uptake
Mouse BMDM plated at 1 x 106 cells on a 6-well plate were treated with FITC-pI:C (10μg/ml)
in the presence of lipofectamine 2000 (at 1:100 dilution, 10μl/ml) or hBD3 (5μg/ml). For treat-
ment with polyI:C in the presence of lipofectamine 2000, media was replaced with optimem
before the addition of polyI:C complexed with lipofectamine 2000 (L-pI:C) and addition of
hBD3 was delayed for 5 min to avoid direct interaction with L-pI:C complexes. After 18 hours
cells were gently washed and gently removed from the dish into PBS containing 1% BSA. Fluo-
rescence was measured with a BD FACSARIAII SORP (BD Biosciences, Oxford, UK), using a
640nm laser (670/14nm bandpass filter). Data analysis was done using FlowJo Version 7.5.5
(Treestar Inc, Olten, Switzerland). This experiment was carried out on 3 different preparations
of BMDMs
Supporting Information
S1 Fig. Creation of DsRed-Tg and EGFP hBD3-Tg mice. A: Transgene vector diagram:
Control and hBD3 expressing vectors were created from pTLC vector (kind gift of Josh Brick-
man). CAG indicate the CAAG promoter (cytomeglavirus enhancer and chicken β-actin) and
the arrow indicates direction of transcription; dsRed indicates the DsRed gene [58]; IRES indi-
cates internal ribosome entry site; Puro indicates puromycin antibiotic resistance gene STOP is
the translation termination signal and pA indicates polyadenylation signal; hBD3 is DEFB103
genomic fragment with exons 1 and 2 indicated by ex1 and ex2; EGFP is Enhanced Green Fluo-
rescent Protein. ES cells (E14(iv), that were 129/Ola derived), were transfected by electropora-
tion with ScaI linearised vector as shown in the upper region of the vector S1A Fig. Cells
expressing DsRed by FACS that were shown to have normal chromosome number of n = 40,
were injected into 3.5d blastocysts from C57Bl/6J mice, to create chimaeric animals. The chi-
maeras were bred with C57Bl/6N mice to establish heterozygotes. Homozygous mice were
established at 7 backcross generations by het x het crosses and homozygotes were identified by
strong DsRed fluorescence evident using a hand held lamp with a light source excitation of
440–460 nm. Homozygotes were validated by breeding i.e. all offspring carried the transgene
when mated with wildtype. The ES clone used to make DsRed-Tgs was treated transiently with
cre recombinase by transfection of a cre expression plasmid (kind gift of Prof. Austin Smith).
These cells now no longer expressed DsRed by FACS but were EGFP positive. B: The site of
transgene integration: of the vector was identified by fluorescent in situ hybridisation (FISH)
and shown by chromosome painting of targeted ES cells to be on chromosome 12. C: hBD3
expression in ES cells with cre treated vector: shows that following CRE treatment the ES
cells express transcript from DEFB103 (hBD3). Mw indicates Øx174 DNA cut with HaeIII and
run on 3% agarose gel. DEFB103 RT-PCR from exon 1 to 2 produces a band of 250bp and this
is only visible when cDNA from the ES cells following cre treatment are used. Mice made from
these cells as described above, were named hBD3-Tg and appeared green when viewed with a
fluorescent light source (excitation 510–540 nm) as heterozygotes. Homozygotes were derived
after 7 backcross generations as for Ds-Red homozygotes described above.D: hBD3-Tg mice
with the DEFB103 transgene express hBD3. BMDM from transgenic DEFB103 expressing
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mice (hBD3Tg) were immunostained with an hBD3 monoclonal antibody (a and b) [32] [32]
or not (b and d) and Texas red labelled second antibody and visualized by fluorescent micros-
copy: (a and c) control mice, (b and d) hBD3-Tg.
(PDF)
S2 Fig. Effects of intraperitoneal polyI:C on hBD3-Tg mice. hBD3-Tg and DSRed-Tg con-
trol mice were injected i.p. with pI:C (100μg/mouse), after 4hr serum cytokine levels were mea-
sured by ELISA. (n = 6 separate mice for each treatment group). In pI:C treated hBD3-Tg mice
there is a trend towards enhanced pI:C induction and reduced CXCL10 induction, compared
to controls, however these data did not reach significance.
(PDF)
S3 Fig. Confocal images to complement Fig 5E. Images showing EEA-1 pseudocoloured red
or green as indicated and no other fluorescence revealed. Fig 5Eviii and 5Evi shown again for
scale and indication of merged images with the pseudocoloured EEA-1. merged Scale bar 10
microns.
(PDF)
S4 Fig. Double and single Mavs and Ticam1 knockouts additional data. Response of
BMDM from (A) Mavs(-/-)/Ticam(-/-) double knockout mice, and (B) Mavs (-/-) or Ticam
(-/-) single KO BMDMwere treated for 18hr with polyI:C (10μg/ml) in the presence and
absence of hBD3 (5μg/ml), with or without lipofectamine (L) as indicated (L-p:C is lipofecta-
mine with polyIC). IFNβ, CXCL10 and TNFα in cell supernatants were measured by ELISA,
p<0.05, p<0.01, p<0.005 student t-test.
(PDF)
S5 Fig. PolyI:C with or without hBD3 does not cause cell death (LDH assay). BMDM from
wt mice were treated for 18hr with polyI:C (pIC) (10μg/ml) in the presence and absence of
hBD3 (5μg/ml). 5x104 cells were exposed to each treatment in triplicate then NADH levels
measured using an LDH-Cytotoxicity Colorimetric Assay (BioVision).
(PDF)
S6 Fig. hBD2 also exacerbates the effect of polyI:C. BMDM from wild type mice were treated
for 18hr with polyI:C (10μg/ml) in the presence and absence of hBD2 (5μg/ml). IFNβ in cell
supernatants was measured by ELISA, p<0.01, student t-test.
(PDF)
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